Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

84 results about "In vivo analysis" patented technology

Analyte detection device and detection method

An analyte detection device includes a shell, a sensor, a transmitter, a battery, a memory, and a processor. The sensor includes an internal part and an external part. The internal part is used to penetrate into a user's subcutaneous skin to obtain a first parameter value. At least one predetermined pair-data set composed of the first parameter value and a second parameter value is pre stored in the memory. The second parameter value is associated with the in vivo analyte parameter information. The processor is programmed to call predetermined pair-data set from the memory, and obtain the second parameter value based on the first parameter by indexed. The transmitter is used to transmit the first parameter value and / or the second parameter value to a remote equipment. The battery is used to provide electric energy.
Owner:MEDTRUM TECH

Mediation of in vivo analyte signal degradation

A sensor (e.g., an optical sensor) that may be implanted within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a sensor housing, an analyte indicator covering at least a portion of the sensor housing, and one or more compounds containing boronate or boronic acid moieties that reduce degradation of the analyte indicator.
Owner:SENSEONICS INC

An in vivo analyte sensor and a method of manufacturing an in vivo analyte sensor

PCT designated stageWO2026008473A1CatheterSensorsAnalyteBiology
The present disclosure refers to an in vivo analyte sensor, comprising: a substrate (20); a conductive layer (21) disposed over at least a portion of the substrate (20); a sensing layer (24) disposed formed on the conductive layer (21), wherein the sensin\g layer (24) forms a sensing area configured to generate one or more signals identifying a monitored analyte level after insertion of the analyte sensor and when maintained in fluid contact with interstitial fluid; and a membrane layer (25) formed at least on the sensing layer (24). The sensing layer (24) is formed with an area sensitivity of 0,2 to 1,5 nA / (mqx / dL) mm2 within the sensing area. Further, a method of manufacturing an in vivo analyte sensor is provided.
Owner:ROCHE DIABETES CARE GMBH +1

Systems and methods utilizing Raman spectroscopy for in vivo analysis

A system for determining characteristics of tissue within a body of a patient may include a medical device. The medical device may include a distal end configured to be advanced within the body of the patient; at least one aperture at the distal end; a laser emitter operable to emit monochromatic light out from the distal end via the at least one aperture and onto target tissue; and at least one photodetector array. The at least one photodetector array may be configured to: receive light incident on the at least one aperture that is one or more of scattered by or reflected from the target tissue; and generate Raman spectroscopy image data based on monochromatic light incident on the at least one aperture, the Raman spectroscopy image data including an array of intensity values.
Owner:BOSTON SCIENTIFIC SCIMED INC

Immunotoxicity analysis and evaluation method and system

The invention relates to the field of biological immunity, and discloses an immunotoxicity analysis and evaluation method and system.The method comprises the steps that immune cells and non-immune cells are cultured, an immune microenvironment of immune cell tissue is constructed, and an in-vitro immune system model of a human body is constructed; inputting an allogenic material into the in-vitro immune system model, and detecting cellular immune parameters of the experimental in-vitro immune system model; the method comprises the following steps: extracting a mouse genome of a mouse, constructing a gRNA-Cas9 compound of a target immune gene, implanting the gRNA-Cas9 compound into a preset mouse fertilized egg, culturing the target gene fertilized egg into a target gene mouse, inputting an exogenous material into the body of the target gene mouse, and analyzing humoral immune parameters of a blood sample; detecting organ parameters of the immune organs, calculating organ coefficients of the immune organs, and analyzing immune organ states of the immune organs; and analyzing an immunotoxicity evaluation report of the allogenic material on the human immune system. According to the invention, the accuracy of immunotoxicity analysis can be improved.
Owner:SUZHOU SAIFU NEW DRUG TECH SERVICE CO LTD +1

Electrochemical sensor systems and methods with reduced signal loss

Electrochemical aptamer (EAB)-based sensors support high frequency real-time monitoring of analytes in vivo. Methods of reducing sensor drift during in vivo placement are described. EAB sensors with non-natural nucleic acids can be used to reduce sensor signal drift. The EAB sensor improves the stability and reduces the signal loss.
Owner:RGT UNIV OF CALIFORNIA

Mediation of in VIVO analyte signal degradation

ActiveCA3130622CAnalyteBoronic acid
A sensor (e.g., an optical sensor) that may be implanted within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a sensor housing, an analyte indicator covering at least a portion of the sensor housing, and one or more compounds containing boronate or boronic acid moieties that reduce degradation of the analyte indicator.
Owner:SENSEONICS INC

Infusion device for continuous glucose monitoring

The present disclosure discloses devices and systems that use a combined sensor and cannula mounted to a body. The combination provides electrical coupling of the sensor to a signal processing device and fluidic coupling of the cannula to a drug delivery source for combined subcutaneous liquid drug delivery and amperometric analyte sensing without the need for multiple skin-piercing elements.SOLUTION: The present disclosure provides systems and devices for combining analyte monitoring with fluid delivery, including devices having a sensor and a cannula in a single component and adapted for use with a combined sensor and cannula. These systems and devices may be used for a variety of applications involving simultaneous in vivo monitoring of analyte concentration and drug delivery.SELECTED DRAWING: Figure 1A
Owner:PACIFIC DIABETES TECHNOLOGIES INC

Electrode arrangements for analyte monitors

A monitor for determining analyte concentrations in vivo includes a housing configured to adhere to a patient's skin, and a sensor member configured to extend from the housing into the patient's skin. The sensor member includes at least a first working electrode and a separate second working electrode that are independently connected to electronics in the housing via separate electrical connections and that function independently from one another.
Owner:LAXMI THERAPEUTIC DEVICES INC

Methods of lag-compensation for analyte measurements, and devices related thereto

PendingUS20260248458A1AnalyteIn vivo analysis
Methods comprising applying a first analyte point measurement filter comprising: receiving, from an in vivo analyte sensor, at least a first, second, and third uncompensated analyte measurement at a first, second and third reference time; determining a first scaled rate-of-change by multiplying a first weighting coefficient and a first rate-of-change, the first rate-of-change computed between the first uncompensated analyte measurement at the first initial reference time to the second uncompensated analyte measurement at the first prior reference time; determining a second scaled rate-of-change by multiplying a second weighting coefficient and a second rate-of-change, the second rate-of-change computed between the first uncompensated analyte measurement at the first initial reference time to the third uncompensated analyte measurement at the second prior reference time; and calculating a first filter lag-compensated point measurement based on the sum of the first uncompensated analyte measurement, the first scaled rate-of-change, and the second scaled rate-of-change.
Owner:ABBOTT DIABETES CARE INC

Systems and methods for electrochemical sensors with reduced signal loss

Electrochemical aptamer-based (EAB) sensors support the high-frequency, real-time monitoring of analyte in vivo. Methods for reducing the sensor drift during in vivo placements are described. EAB sensors with non-natural nucleic acid can be used to reduce sensor signal drift. The EAB sensors have improved stability and reduced signal loss.
Owner:RGT UNIV OF CALIFORNIA

A method of identifying variants in gene products from gene constructs used for cell therapy applications

ActiveCN117597738BGene productRNA Sequence
A method of ensuring that a gene product used for cell therapy is free of the risk of reduced efficacy or toxicity due to production of an undesirable variant. The method includes performing a computer simulation analysis on a gene construct to identify and alter sequences that can cause variants. In addition, the method includes performing an in vivo analysis consisting of RNA sequences based on the product of the construct. Variant detection can then be performed based on gap reads from the RNA sequences to determine variant expression levels, variant significance. If the identified variants are not acceptable, the method can include repeating the computer simulation analysis.
Owner:KITE PHARMA INC

Display interface interaction method and system

According to the display interface interaction method and system, target user data of a target user are obtained, and the target user data comprise user related data and / or sensor related data; the terminal equipment comprises a display interface, and the display interface displays content related to the target user; the display interface is provided with at least one dynamic display area, and dynamic information is displayed in the dynamic display area; based on the target user data, generating at least one dynamic content through an artificial intelligence model; and displaying dynamic information containing dynamic content in the dynamic display area in response to a user behavior. Information on the display interface can be dynamically displayed, user interaction can be supported, and corresponding content can also be dynamically changed, so that a user is attracted to interact on the display interface, and the utilization rate of the in-vivo analyte monitoring system is improved.
Owner:ANDON HEALTH CO LTD

Systems, devices and methods for analyte sensor insertion

Systems, devices and methods are provided for inserting at least a portion of an in vivo analyte sensor, such as a dermal sensor, for sensing an analyte level in a bodily fluid of a subject. An applicator is positioned against a skin surface and a force is applied to the applicator causing at least a portion of a sharp and an in vivo analyte sensor to be positioned in the body of the subject. In particular, disclosed herein are embodiments of applicators designed to prevent premature sharp withdrawal and / or reduce the likelihood of improper sensor insertion. Also disclosed are embodiments of applicators including sharp modules having an angled sharp which can be configured to create an insertion path for a sensor.
Owner:ABBOTT DIABETES CARE INC

Focused sterilization and sterilized sub-assemblies for analyte monitoring systems

To provide systems, devices, and methods for assembling an applicator and a sensor control device for use in an in vivo analyte monitoring system.SOLUTION: A system includes: a sensor applicator 102; a sensor control device 302 arranged within the sensor applicator and including an electronics housing and a sensor 316 extending from a bottom of the electronics housing; and a cap 210 coupled to one of the sensor applicator and the sensor control device, where the cap is removable prior to deploying the sensor control device from the sensor applicator.SELECTED DRAWING: Figure 6B
Owner:ABBOTT DIABETES CARE INC

Noise rejection methods and apparatus for sparsely sampled analyte sensor data

Systems, methods and apparatus are provided for rejecting noise from sparsely sampled analyte sensor data. Embodiments of the present disclosure include receiving a raw set of sensor data from an on-body device including an in vivo analyte sensor, determining an interpolation-based estimate of an analyte level over time based on the raw set of sensor data, determining an extrapolation-based estimate of the analyte level over time based on the raw set of sensor data, determining a combined estimate of the analyte level over time based on the interpolation-based estimate and the extrapolation-based estimate, and displaying a representation of the combined estimate of the analyte level over time on an output device. Numerous additional aspects are disclosed.
Owner:ABBOTT DIABETES CARE INC

Interactive content generation method and system for in vivo analyte monitoring system

The present specification provides an interaction content generation method and an in vivo analyte monitoring system. The generation method comprises the following steps: obtaining target user data of a target user, wherein the target user data comprises user-related data and / or analyte-related data; and providing the target user data to an artificial intelligence model in response to detecting that the generation condition is triggered, and guiding the artificial intelligence model to generate interaction content.
Owner:ANDON HEALTH CO LTD

Methods and apparatus for in VIVO molecular characterisation

An apparatus for in vivo profiling a region of biological tissue to determine its state of mutation is provided. The apparatus includes a light source configured to generate at least one light beam, an optical arrangement configured to form the light beam into an optical probe beam for illuminating the region of biological tissue and receiving a Raman backscattered optical signal from the region of biological tissue, wherein the optical arrangement is further configured to filter the Raman backscattered optical signal to generate a filtered optical signal. The apparatus further comprises an optical detector configured to receive the filtered optical signal to generate a corresponding detector signal including one or more components indicative of one or more molecular species present in the region of biological tissue; and a data processing arrangement configured to process the detector signal to determine from the one or more components a concentration of the one or more molecular species to compute the state of mutation of the biological tissue.
Owner:NEUROLASE LTD

Novel myd88 inhibitor for treatment of autoimmune diseases and uses thereof

Toll-like receptors play a crucial role in responding to infections by microbial pathogens, but their abnormal signaling is associated with exacerbating several immune diseases, including psoriasis and EAE. TLR activation leads to recruitment of adapter proteins, of which MyD88 is very important. MyD88 activates NF-kB and MAP kinases to initiate an inflammatory response to infection or tissue damage. In the present invention, an MyD88 inhibitory peptide targeting an MyD88 interaction interface was developed using a reasonable peptide design approach, and the efficacy thereof was evaluated in human and mouse cell lines. As a result of in vitro and in vivo analysis, it has been shown that the MyD88 inhibitory peptide MyDIP2-4 effectively inhibits MyD88-mediated signaling in TLR and IL-1R-mediated pathways. Through surface plasmon resonance, it was confirmed that MyDIP2-4 specifically interacts with the MyD88 protein in a dose-dependent manner. MyDIP2-4 significantly inhibited IL-23 and Ki-67 in imiquimod-induced psoriasis models, and downregulated cytokines including IL-6 and IFN-γ in EAE. These results suggest that MyDIP2-4 is a promising candidate for the treatment of autoimmune diseases. Therefore, targeting the TIR domain of MyD88 through a reasonable peptide design can provide a new strategy for developing therapeutic agents for immune diseases such as psoriasis and EAE.
Owner:S&K THERAPEUTICS

An analysis and evaluation method and system for immunotoxicity

The present invention relates to the field of biological immunity, and discloses a method and system for analyzing and evaluating immunotoxicity, the method comprising: culturing immune cells and non-immune cells, constructing an immune microenvironment of immune cell tissue, and constructing an in vitro immune system model of the human body; inputting exogenous substances into the in vitro immune system model, and detecting the cellular immune parameters of the experimental in vitro immune system model; extracting the mouse genome of mice, constructing the gRNA-Cas9 complex of the target immune gene, implanting the gRNA-Cas9 complex into a preset mouse fertilized egg, cultivating the target gene fertilized egg into a target gene mouse, inputting exogenous substances into the body of the target gene mouse, and analyzing the humoral immune parameters of the blood sample; detecting the organ parameters of the immune organ, calculating the organ coefficient of the immune organ, and analyzing the immune organ status of the immune organ; analyzing the immunotoxicity evaluation report of the exogenous substance on the human immune system. The present invention can improve the accuracy of immunotoxicity analysis.
Owner:SUZHOU SAIFU NEW DRUG TECH SERVICE CO LTD +1

Medical devices and methods

PendingUS20260253722A1AnalyteBody fluid
Methods and devices to monitor an analyte in body fluid are provided. Embodiments include continuous or discrete acquisition of analyte related data from a transcutaneously positioned in vivo analyte sensor automatically or upon request from a user.
Owner:ABBOTT DIABETES CARE INC

Method and devices for analyte monitoring calibration

Methods, systems and devices for providing improved calibration accuracy of continuous and / or in vivo analyte monitoring systems based at least in part on insulin delivery information are provided. Many of the embodiments disclosed herein can determine appropriate conditions for performing a calibration of the analyte sensor in view of the scheduled delivery of insulin or administered insulin amount. One or more other parameters or conditions can also be incorporated to improve calibration accuracy including, for example, the physiological model associated with a patient, meal information, exercise information, activity information, disease information, historical physiological condition information, as well as other types of information. Furthermore, according to some embodiments, calibration of the analyte sensor can be delayed or not performed at all, if appropriate conditions are not met.
Owner:ABBOTT DIABETES CARE INC

Systems, devices, and methods for analyte monitoring

A system, device, and method are provided for inserting at least a portion of an in vivo analyte sensor to sense an analyte level in a bodily fluid of a subject. In particular, various embodiments of sensor control devices and components thereof are disclosed herein that are designed to reduce the size and number of internal components of the sensor control device. In addition, embodiments of the sensor control devices and related sensor features disclosed herein are designed to increase the comfort and convenience of a subject.
Owner:ABBOTT DIABETES CARE INC

Small-scale analyte sensors

A monitor for determining analyte concentrations in vivo includes a housing configured to adhere to the skin of a subject, a sensor body configured to extend from the housing into a patient's skin, the sensor body being elongate and extending along a longitudinal axis in a length direction, and further having a width and a thickness each measured perpendicular to the length, and an analyte sensing region formed on the sensor body. The analyte sensing region has opposite ends in the length direction, where a maximum length of the analyte sensing region measured between the opposite ends is 80 μm or less.
Owner:LAXMI THERAPEUTIC DEVICES INC

Medical devices and methods

Methods and devices to monitor an analyte in body fluid are provided. Embodiments include continuous or discrete acquisition of analyte related data from a transcutaneously positioned in vivo analyte sensor automatically or upon request from a user. The in vivo analyte sensor is coupled to an electronics unit holding a memory with instruction to cause processing circuitry to initiate a predetermined time period that is longer than a predetermined life of the sensor, during the predetermined time period, convert signals from the sensor related to glucose to respective corresponding glucose levels, without relying on any post-manufacture independent analyte measurements from a reference device, and at the expiration of the predetermined time period, disable, deactivate, or cease use of one or more feature.
Owner:ABBOTT DIABETES CARE INC

Reducing in vivo analyte signal degradation using multiple metals

A sensor (e.g., an optical sensor) that can be implanted within a living animal (e.g., a human) and used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal, the sensor including a sensor housing, an analyte indicator covering at least a portion of the sensor housing, and a multi-metal protection system including multiple metals incorporated within and / or proximate to a surface of the analyte indicator that reduces deterioration of the analyte indicator.
Owner:SENSEONICS INC

Rich media content generation method and system for in vivo analyte monitoring system

The invention provides a rich media content generation method for an in-vivo analyte monitoring system and the in-vivo analyte monitoring system. The method comprises the steps of calling target user data and / or a knowledge base to generate target content in response to user behavior operation and / or triggering of a content generation condition; determining a target format corresponding to the target content; generating target rich media content based on the target content and the target format; and displaying the target rich media content on a target interface of the terminal device.
Owner:ANDON HEALTH CO LTD

Analyte sensor members with delayed sensor activation

PCT designated stageWO2026080819A1CatheterSensorsAnalyteBiology
A monitor for determining analyte concentrations in vivo includes a housing configured to adhere to a patient's skin, and a sensor member configured to extend from the housing into the patient's skin. The sensor member includes at least a first working electrode and a separate second working electrode that are configured to be activated at different times upon implantation of the sensor member into the patient's skin.
Owner:LAXMI THERAPEUTIC DEVICES INC

Reader device for displaying analyte data having short circuit detection and capable of detecting safety of charger device

A reader device for displaying analyte data includes a housing, a charging port configured to engage with a connector of a charging device, and a power source configured to be charged by the charging device. The reader devices includes communication circuitry for receiving analyte data from a sensor control device having an in vivo analyte sensor, and a display for displaying analyte data. The reader device includes a first temperature sensor configured to measure a first temperature of the charging port, and a second temperature sensor configured to measure an internal temperature within the housing. A processing device of the reader device receives the first and second temperatures, determines a difference between the first and second temperatures, and outputs an alert when the difference exceeds a temperature difference threshold.
Owner:ABBOTT DIABETES CARE INC

Rich media content generation method and system for in vivo analyte monitoring system

The invention provides a rich media content generation method for an in-vivo analyte monitoring system and the in-vivo analyte monitoring system. The method comprises the steps of obtaining a content generation instruction, and guiding an artificial intelligence model to generate target rich media content meeting a target requirement at least based on the content generation instruction under the condition of determining that the content generation instruction has the target requirement; and outputting the target rich media content. Wherein the target demand is a demand for generating rich media content, and the content generation instruction is used for indicating to generate target content meeting the target demand.
Owner:ANDON HEALTH CO LTD